MEDISEARCHER NEWS
European Union · Achondroplasia treatment · 20 October 2026
In brief
- The European Medicines Agency’s human medicines committee has recommended EU marketing authorisation for Yuviwel (navepegritide) for children with achondroplasia.
- Yuviwel is administered by subcutaneous injection once a week, offering a substantially less frequent dosing schedule than the existing daily CNP-based treatment Voxzogo.
- EMA’s recommendation covers children aged 2 years and older whose growth plates have not closed and whose achondroplasia has been confirmed by appropriate genetic testing.
- In a randomized, double-blind, placebo-controlled 52-week trial, Yuviwel improved annualised growth velocity by 1.49 cm per year compared with placebo.
- The most common side effects identified by EMA are injection-site reactions and hypertrichosis, or abnormal hair growth.
- Yuviwel is not yet authorised in the European Union. The positive CHMP opinion must now be followed by a European Commission decision.
A once-weekly treatment for children with achondroplasia has moved a major step closer to European Union authorisation after the European Medicines Agency’s human medicines committee issued a positive opinion for Yuviwel (navepegritide).
The Committee for Medicinal Products for Human Use (CHMP) adopted its positive opinion on 15 October 2026, recommending that Yuviwel receive an EU marketing authorisation.
The medicine is intended for children aged 2 years and older with genetically confirmed achondroplasia whose growth plates remain open.
One of the most significant practical differences between Yuviwel and the established EU treatment Voxzogo is dosing frequency: Yuviwel is designed to be injected once a week, while Voxzogo is administered once daily.
The EMA recommendation is based on clinical evidence showing that Yuviwel increased annualised growth velocity compared with placebo over 52 weeks.
However, the regulatory process is not complete. A positive CHMP opinion is not itself an EU marketing authorisation. The European Commission must now make the final authorisation decision.
What is Yuviwel?
Yuviwel is the brand name for navepegritide, a medicine developed for the treatment of achondroplasia in children.
Navepegritide is a prodrug containing C-type natriuretic peptide, commonly abbreviated to CNP.
After administration, active CNP is released and binds to natriuretic peptide receptor B, or NPR-B.
This promotes processes involved in cartilage-cell development and bone growth.
Yuviwel has been designed to provide prolonged exposure to active CNP, allowing the medicine to be administered once weekly rather than every day.
What is achondroplasia?
Achondroplasia is a genetic skeletal condition that affects bone growth and is the most common form of disproportionate short stature.
It is caused by pathogenic variants in the FGFR3 gene, which encodes fibroblast growth factor receptor 3.
FGFR3 normally helps regulate bone growth. In achondroplasia, the altered receptor is excessively active, interfering with the normal development and growth of bones formed through cartilage.
The condition affects bones throughout the body, including the skull, spine, arms and legs.
Although short stature is its most visible characteristic, achondroplasia can also be associated with medical complications involving the spine, airways, ears and other parts of the body.
Management therefore extends beyond height and can require multidisciplinary medical care throughout childhood and adulthood.
Who could receive Yuviwel in the EU?
The indication recommended by the CHMP covers children who meet three main criteria.
They must:
- be 2 years of age or older;
- have growth plates, or epiphyses, that have not yet closed; and
- have a diagnosis of achondroplasia confirmed through appropriate genetic testing.
Growth plates are areas of developing tissue near the ends of children’s bones where longitudinal bone growth occurs.
Once these plates close at skeletal maturity, medicines intended to increase longitudinal bone growth would no longer be expected to work in the same way.
EMA also states that Yuviwel should be prescribed and treatment monitored by physicians experienced in diagnosing and managing children with achondroplasia.
How effective is Yuviwel?
The main evidence cited by EMA comes from a randomized, double-blind, placebo-controlled 52-week clinical trial.
The study evaluated whether once-weekly navepegritide could increase annualised growth velocity in children with achondroplasia.
EMA reports that Yuviwel improved annualised growth velocity by 1.49 cm per year compared with placebo.
The US FDA reviewed the same pivotal programme when considering Yuviwel earlier in 2026.
In the FDA-reviewed trial, 84 children with genetically confirmed achondroplasia who had not previously received treatment participated in the randomized study. Fifty-seven received Yuviwel once weekly and 27 received placebo.
The FDA reported mean annualised growth velocities of approximately 5.9 cm per year with Yuviwel compared with 4.4 cm per year with placebo, corresponding to a treatment difference of approximately 1.5 cm per year.
The trial then continued into an open-label extension, and children who received Yuviwel for two years maintained their growth rate during the second year.
Does Yuviwel make children 1.49 cm taller?
The figure requires careful interpretation.
The 1.49 cm result refers to the difference in annualised growth velocity between Yuviwel and placebo during the 52-week trial.
It should not be interpreted as a guarantee that every child treated with Yuviwel will gain exactly 1.49 cm of additional height each year.
Individual growth can vary considerably according to factors including age, stage of skeletal development and individual response to treatment.
It is also not yet known from the pivotal one-year comparison exactly how treatment will affect final adult height.
Longer-term evidence will therefore remain important.
How often is Yuviwel given?
Yuviwel is administered by subcutaneous injection once each week.
Subcutaneous medicines are injected into the tissue beneath the skin.
The once-weekly dosing schedule is one of Yuviwel’s most distinctive characteristics.
For a treatment that may be used over a substantial part of childhood, reducing injection frequency can considerably change the practical treatment burden for children and their families.
A weekly schedule represents approximately 52 scheduled injections per year, compared with approximately 365 for a treatment administered every day.
How does Yuviwel compare with Voxzogo?
Yuviwel would not be the first medicine authorised in the European Union for children with achondroplasia.
Voxzogo (vosoritide) has been authorised in the EU since 2021 and is currently indicated for children with achondroplasia from 4 months of age whose growth plates have not closed.
Both treatments act through biological pathways involving C-type natriuretic peptide and are intended to counteract abnormal signalling affecting bone growth.
However, there are important practical differences.
Voxzogo is administered by subcutaneous injection once daily, whereas Yuviwel is designed for once-weekly administration.
The proposed age ranges also differ: the current Voxzogo indication begins at 4 months, while the recommended Yuviwel indication begins at age 2.
These differences do not establish that one medicine is clinically superior to the other.
Results from separate clinical trials should not be treated as direct head-to-head comparisons, and treatment decisions will depend on factors including age, medical history, response to treatment, safety, availability and individual clinical circumstances.
What are the side effects of Yuviwel?
According to EMA, the most common side effects associated with Yuviwel are:
- injection-site reactions; and
- hypertrichosis, meaning abnormal or excessive hair growth, including around the injection site.
Other safety information will be described in the medicine’s European Summary of Product Characteristics and patient leaflet if the European Commission grants marketing authorisation.
Because treatment is intended for children and may continue over an extended period, ongoing safety monitoring will remain important.
Is Yuviwel already approved in the United States?
Yes.
The US Food and Drug Administration approved Yuviwel on 27 February 2026 to increase linear growth in children aged 2 years and older with achondroplasia and open growth plates.
The FDA granted the medicine accelerated approval.
This distinction matters.
The US approval was based on improvement in annualised growth velocity, which FDA considers an intermediate clinical endpoint reasonably likely to predict meaningful benefit.
Continued US approval may depend on confirmation of clinical benefit, and an ongoing post-approval study is intended to determine whether treatment improves final adult height.
The European regulatory procedure is separate, and the CHMP has now recommended Yuviwel for EU marketing authorisation.
Is Yuviwel approved in the European Union?
Not yet.
The CHMP adopted a positive opinion for Yuviwel on 15 October 2026.
This is one of the final major scientific stages of the EU centralised medicine-authorisation process, but a CHMP recommendation is not itself a marketing authorisation.
The recommendation now goes to the European Commission, which will decide whether to grant an authorisation valid across EU member states.
EMA currently lists Yuviwel as pending a European Commission decision.
MediSearcher’s EU medicine access guide explains how European medicine authorisation and national access systems interact.
When could Yuviwel become available in Europe?
European Commission authorisation would clear the central regulatory stage, but it would not necessarily mean that children throughout Europe could immediately begin treatment.
Medicine pricing, reimbursement and routine healthcare access are largely determined at national level.
Individual countries may conduct health-technology assessments, negotiate prices and establish reimbursement criteria before Yuviwel becomes routinely funded through their healthcare systems.
This means access could begin at different times in Germany, France, Italy, Spain, the Netherlands, Ireland, Sweden, Poland, Malta and other EU member states.
MediSearcher’s guide to prescription costs and reimbursement across the EU explains why an EU-authorised medicine can become routinely accessible at different times in different countries.
Could Germany be one of the first EU countries to get Yuviwel?
The manufacturer has indicated that, if European Commission authorisation is granted as expected, it intends to launch Yuviwel in Germany in early 2027.
That is a company launch plan rather than a regulatory guarantee, and actual access will also depend on the German pricing and reimbursement process.
Nevertheless, Germany could become one of the first European markets where the medicine becomes commercially available following EU authorisation.
Launch timing in other member states may differ.
Why could once-weekly dosing matter for families?
The significance of weekly dosing goes beyond convenience.
Children receiving a daily injectable medicine can face a substantial cumulative treatment burden over months and years.
For families, treatment can involve storing and preparing medication, incorporating injections into daily routines, travelling with medicine and managing a child’s response to repeated injections.
A once-weekly schedule does not remove these responsibilities, but it substantially reduces the number of scheduled injections.
Whether that translates into better treatment adherence, quality of life or long-term outcomes will require real-world evidence after the medicine becomes available.
Does Yuviwel cure achondroplasia?
No.
Yuviwel does not remove or correct the underlying FGFR3 genetic variant that causes achondroplasia.
Instead, the medicine is designed to modify one of the biological signalling pathways affected by the condition and promote bone growth while a child’s growth plates remain open.
It should therefore be described as a treatment for achondroplasia rather than a genetic cure.
Children with achondroplasia may continue to require monitoring and care for other medical complications associated with the condition regardless of growth treatment.
What happens next for Yuviwel in Europe?
The immediate next milestone is the European Commission’s decision on marketing authorisation.
If authorisation is granted, attention will then move toward commercial launches, national health-technology assessments, pricing negotiations and reimbursement decisions.
Those national processes will determine when eligible children can routinely access treatment and whether it is publicly reimbursed in individual countries.
Longer-term clinical evidence will also be important, particularly evidence concerning sustained growth, final adult height, safety and broader health outcomes.
MediSearcher will update this article when the European Commission announces its decision and as significant launch, pricing or reimbursement developments emerge across EU member states.
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: This article was reviewed for source accuracy, medicine-regulation context and consistency with MediSearcher’s editorial standards. Information about Yuviwel’s proposed EU indication, mechanism, dosing, Phase 3 evidence and adverse effects was checked against European Medicines Agency information. US approval status and the distinction between annualised growth velocity and confirmed benefit on final adult height were checked against US Food and Drug Administration regulatory information.
Last reviewed: 20 October 2026
Sources and verification
MediSearcher reviewed the following primary and authoritative sources when preparing this article:
- European Medicines Agency: Yuviwel (navepegritide) regulatory overview and CHMP positive opinion, adopted 15 October 2026
- European Medicines Agency: CHMP meeting highlights, 12–15 October 2026
- US Food and Drug Administration: FDA approval of Yuviwel for pediatric patients with achondroplasia, including pivotal efficacy and safety evidence
- US Food and Drug Administration: integrated regulatory review of Yuviwel (navepegritide), including Phase 3 annualised growth velocity results and accelerated-approval requirements
- European Medicines Agency: Voxzogo (vosoritide) EU authorisation and current indication for achondroplasia
MediSearcher provides general information about medicines, medicine regulation and healthcare access. Yuviwel (navepegritide) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use but, as of 20 October 2026, has not yet received European Commission marketing authorisation. Treatment decisions for children with achondroplasia should be made with clinicians experienced in managing the condition. Availability, reimbursement and eligibility may differ between countries following authorisation. This article does not provide personal medical advice.